AUS
NZ
UK
CA
USA
IND
Highlights
- Nanosonics shares jump after US FDA greenlight
- CORIS tool sees early investor excitement
- Analysts flag slow rollout and valuation concerns
Nanosonics (ASX:NAN) saw a strong rally in its share price following the US Food and Drug Administration's (FDA) approval of its new infection prevention device, CORIS. The company, known for developing disinfection technologies used in hospitals, recorded a 14% jump in its stock price on Thursday, closing at $4.98. The positive momentum carried into Friday with a further 2.2% lift in early afternoon trading.
The surge in investor enthusiasm was sparked by the regulatory nod for CORIS, a tool designed to disinfect endoscopes and reduce the risk of infections in medical procedures. The approval marks a significant milestone for the company, potentially opening up new market opportunities in the infection control space within the US healthcare system.
Despite the excitement in the market, some analysts are urging a more tempered outlook. A recent assessment from JPMorgan suggests that the current valuation of Nanosonics may be stretched in light of the recent rally. The firm revised its stance on the stock, noting that the sharp rise appears to be an overreaction to the FDA news.
One of the key concerns highlighted is the anticipated pace of the CORIS rollout. The launch is expected to be gradual as the company navigates operational adjustments and seeks additional regulatory clearances. Moreover, there remains limited visibility around pricing, which adds another layer of complexity in forecasting its financial impact.
While CORIS presents a promising growth avenue for Nanosonics (NAN), the company's own commentary hints at a cautious timeline. According to analysts, the full commercial potential may take time to materialise, with several steps required before the device can achieve widespread adoption.
As part of the update, the price target on Nanosonics was adjusted modestly to $4.00, up from a previous estimate of $3.90. This reflects a recognition of the longer-term opportunity while also accounting for the short-term challenges around execution and scaling.
Investors are closely watching how the company capitalises on the CORIS opportunity and how quickly it can translate regulatory approval into meaningful commercial outcomes. As the healthcare sector continues to prioritise infection control solutions, Nanosonics (NAN) finds itself in a potentially advantageous position — though one that will require patience and strategic execution.
